相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy A Single Institutional Experience With 359 Cases
Rohit Bhargava et al.
CANCER (2010)
Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer
Eitan Amir et al.
CANCER TREATMENT REVIEWS (2010)
Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
Massimo Cristofanilli et al.
CLINICAL CANCER RESEARCH (2010)
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
M. D. Green et al.
ANNALS OF ONCOLOGY (2009)
Aromatase Inhibitors and Breast Cancer
Luciana Furtado Macedo et al.
STEROID ENZYMES AND CANCER (2009)
Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen
Gauri Sabnis et al.
CANCER RESEARCH (2009)
Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer
Valentina Guarneri
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
MOLECULAR ORIGINS OF CANCER Gene-Expression Signatures in Breast Cancer
Christos Sotiriou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
Henning Mouridsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M. Untch et al.
ANNALS OF ONCOLOGY (2008)
Circumventing de novo and acquired resistance to trastuzumab: New hope for the care of ErbB2-positive breast cancer
Martine Piccart
CLINICAL BREAST CANCER (2008)
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
Grazia Arpino et al.
ENDOCRINE REVIEWS (2008)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
Robert J. Paridaens et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Birgitte B. Rasmussen et al.
LANCET ONCOLOGY (2008)
Targeting Her-2/neu in breast cancer: As easy as this!
Hamdy Azim et al.
ONCOLOGY (2008)
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer
Ian E. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers
P. Kelly Marcom et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
G. Valabrega et al.
ANNALS OF ONCOLOGY (2007)
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
Wenle Xia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
M Dowsett et al.
ANNALS OF ONCOLOGY (2006)
Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers
WL Xia et al.
CANCER RESEARCH (2006)
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts
JM du Manoir et al.
CLINICAL CANCER RESEARCH (2006)
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
T Fujita et al.
BRITISH JOURNAL OF CANCER (2006)
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2005)
Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance
G Arpino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
WL Xia et al.
ONCOGENE (2005)
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial
F Boccardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
M De Laurentiis et al.
CLINICAL CANCER RESEARCH (2005)
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole
D Jelovac et al.
CANCER RESEARCH (2005)
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial
A Polychronis et al.
LANCET ONCOLOGY (2005)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
RC Coombes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site
LN Petz et al.
MOLECULAR ENDOCRINOLOGY (2004)
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
WL Xia et al.
ONCOGENE (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
J Shou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Overcoming endocrine therapy resistance by signal transduction inhibition
M Ellis
ONCOLOGIST (2004)
Combining trastuzumab (Herceptin®) with hormonal therapy in breast cancer:: what can be expected and why?
A Jones
ANNALS OF ONCOLOGY (2003)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - Results of the ATAC (arimidex, tamoxifen alone or in comhination) trial efficacy and safety update analyses
CANCER (2003)
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen
A Lipton et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer
XJ Cui et al.
MOLECULAR ENDOCRINOLOGY (2003)
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
CK Osborne et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells
JM Knowlden et al.
ENDOCRINOLOGY (2003)
Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
A Lipton et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor
JF de Mora et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
The multiple roles of PTEN in tumor suppression
A Di Cristofano et al.
CELL (2000)
The SMRT corepressor is regulated by a MEK-1 kinase pathway: Inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export
SH Hong et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
